Skip to Content

'
Donna M. Weber, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Instructor, Department of Hematology, UT M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1988 Southern Illinois University School of Medicine, Sprinfield, IL, MD, MD
1984 University of Illinois, Champaign-Urbana, BS, Microbiology

Postgraduate Training

1991-1994 Fellowship: Medical Oncology/Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX
1988-1991 Internship and Residency:, Internal Medicine, Southern Illinois University, Springfield

Board Certifications

2006 Medical Oncology
1996 Hematology
1991 American Board of Internal Medicine

Experience/Service

Administrative Appointments/Responsibilities

Clinical Associate Medical Director of Myeloma, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 5/2012-present

Other Appointments/Responsibilities

Member of the Scientific Advisory Board, Multiple Myeloma Research Foundation (MMRF) Scientific Advisory Board, International, 2006-2009
Chairman, Relapsed Myeloma Subcommittee, ASH/FDA Workshop: Clinical Endpoints in Multiple Myeloma,, National, 2006
Member, NCI Working Group, Waldenstrom's Macroglobulinemia, National, 2000
Member Scientific Advisory Board, International Waldenstrom’s Macroglobulinemia Foundation (IWMF), International, 1998-present
Member Scientific Advisory Board, Research Fund for Waldenstrom’s (RFW), National, 1998-2000
Member, NCCN Myeloma Guidelines Committee, National, 1996-present

Institutional Committee Activities

Member, Anesthesiology Chairman Search Committee, 2008-present
Member, Myeloma Department Guidelines Subcommittee of the Clinical Effectiveness Committee (lead responsible for guideline development), 2008-present
Member, Clinical Effectiveness Committee, 2008-2012
Member, Alternate Clinical Effectiveness Committee, 2007-2008
member, Transfusion Committee, 2004-2013
Chairman, Medication Process Task Force of the Pharmacy & Therapeutic Committee, 1998-2002
Member, Department of Lymphoma/Myeloma, Faculty Development Committee of the Faculty Senate, 1998-2002
Faculty Senate Representative, Department of Lymphoma/Myeloma, 1997-2000
member, Division of Cancer Medicine, Fellowship Committee, 1996-2001

Honors and Awards

2008-present Castle Connolly, Top Doctors (Regional)
2006-present Who's Who in American Business Women
2005-present Best Doctors in America
1993-1994 Achievement in Research Award, U.T. M. D. Anderson Cancer Center
1990 First Place, Vignette Competition, Illinois Scientific Meeting, American College of Physicians
1990 Second Place, Vignette Competition, Illinois Associates Meeting, American College of Physicians
1989-1990 Barry Breen Memorial Award, Outstanding Medicine Resident
1988-1989 Barry Breen Memorial Award, Runner-up, Outstanding Medicine Intern

Professional Memberships

American Society of Hematology
Member, 1/1993-present
Harris County Medical Society, Houston, TX
Member, 5/2007-present
Illinois State Medical Society
Secretary/Editor, Medical Student Section Governing, 1/1986-1/1989
Sangamon County Medical Society
Resident Representative/Board of Directors, 1/1988-1/1989
Sangamon County Medical Society
Student Representative/Board of Directors, 1/1986-1/1989
Texas Medical Association, TX
Member, 6/1997-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 11:1311-5, 7/1993. PMID: 8315427.
2. Dimopoulos MA, Weber D, Delasalle KB, Alexanian R. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma. Cancer 72:2589-92, 11/1993. PMID: 8402480.
3. Sutton RC, Wever DM, Whimbey EE, Gibbs HR, Dhingra K. Catheter-associated left valvular endocarditis due to corynebacterium. Cancer Bulletin 45:460-465, 1993.
4. Dimopoulos MA, Weber DM, Kantarjian H, Keating M, Alexanian R. 2Chlorodeoxyadenosine therapy of patients with Waldenstrom macroglobulinemia previously treated with fludarabine. Ann Oncol 5:288-9, 3/1994. PMID: 7514439.
5. Dimopoulos MA, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, Rose E, Cabanillas F, Keating M, Alexanian R. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12:2694-8, 12/1994. PMID: 7989946.
6. Weber DM, Dimopoulos MA, Anandu DP, Pugh WC, Steinbach G. Regression of gastric lymphoma of mucosa-associated lymphoid tissue with antibiotic therapy for Helicobacter pylori. Gastroenterology 107:1835-8, 12/1994. PMID: 7958698.
7. Dimopoulos, MA, Arbuck S, Huber M, Weber D, Luckett R, Delasalle K, Alexanian R:. Primary therapy of multiple myeloma with paclitaxel (taxol). . Annals of Oncology 5:757-9, 1994.
8. Weber D, Dimopoulos M, Sinicrope F, Alexanian R. VAD-cyclosporine therapy for VAD-resistant multiple myeloma. Leuk Lymphoma 19:159-63, 9/1995. PMID: 8574163.
9. Daliani D, Weber D, Alexanian R. Light-heavy chain deposition disease progressing to multiple myeloma. Am J Hematol 50:296-8, 12/1995. PMID: 7485106.
10. Moulopoulos LA, Dimopoulos MA, Smith TL, Weber DM, Delasalle KB, Libshitz HI, Alexanian R. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 13:251-6, 1995. PMID: 7799027.
11. Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 6:49-52, 1995. PMID: 7710983.
12. Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol 52:77-81, 6/1996. PMID: 8638645.
13. Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, Gajewski J, Andersson B, Khouri I, Przepiorka D, von Wolff B, Delasalle K, Korbling M, Seong D, Alexanian R, Champlin R. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 15:667-73, 2/1997. PMID: 9053492.
14. Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. Br J Haematol 97:810-4, 6/1997. PMID: 9217181.
15. Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, Huh Y, Glassman A, Champlin R, Alexanian R. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 101:189-94, 4/1998. PMID: 9576200.
16. Alexanian R, Weber D, Liu F. Differential diagnosis of monoclonal gammopathies. Arch Pathol Lab Med 123:108-13, 2/1999. PMID: 10050782.
17. Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol 52:245-9, 9/1999. PMID: 10580871.
18. Alexanian R, Weber D, Dimopoulos M, Delasalle K, Smith TL. Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma. Am J Hematol 65:204-9, 11/2000. PMID: 11074536.
19. Alexanian, R, Weber D. Thalidomide for resistant and relapsing myeloma. Seminars in Hematology 37:22-25, 2000.
20. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, Champlin R. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 27:1037-43, 5/2001. PMID: 11438818.
21. Mansoor A, Medeiros LJ, Weber DM, Alexanian R, Hayes K, Jones D, Lai R, Glassman A, Bueso-Ramos CE. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol 116:543-9, 10/2001. PMID: 11601139.
22. Alexanian, R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. American Society of Hematology (Blood):163a, 2001.
23. Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 94(5):1532-7, 3/2002. PMID: 11920511.
24. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 13(7):1116-9, 7/2002. PMID: 12176792.
25. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno NT, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 30(6):367-73, 9/2002. PMID: 12235521.
26. Alexanian R, Weber D, Delasalle K, Cabanillas F, Dimopoulos M. Asymptomatic Waldenstrom's macroglobulinemia. Semin Oncol 30(2):206-10, 4/2003. PMID: 12720137.
27. Weber D, Treon SP, Emmanouilides C, Branagan AR, Byrd JC, Blade J, Kimby E. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30(2):127-31, 4/2003. PMID: 12720121.
28. Weber DM. Strategies in treating newly diagnosed or untreated multiple myeloma patients. From the Multiple Myeloma Research Foundation. Oncology (Williston Park) 17(6):765-7, 6/2003. PMID: 12846120.
29. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121(5):768-71, 6/2003. PMID: 12780791.
30. Ahmed M, Giles F, Joe Y, Weber DM, Jilani I, Manshouri T, Giralt S, De Lima M, Keating M, Albitar M. Use of Plasma DNA in Detection of Loss Heterozygosity in Patients with Multiple Myeloma. Eur J Haematol 71((3)):174-8, 9/2003.
31. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 40(4 Suppl 4):3-7, 10/2003. PMID: 15015890.
32. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 21(23):4444-54, 12/2003. PMID: 14645435.
33. Weber, D, Dimopoulos M, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-chlorodeoxyadenosine alone or in combination for Waldenstrom’s macroglobulinemia. Seminars in Oncology. 30(2):243-247, 2003.
34. Kyle on behalf of International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders. A Report of the International Myeloma Working Group. International Myeloma Working Group , British Journal of Hematology 121:749-757, 2003.
35. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21(1):16-9, 2003. PMID: 12506164.
36. Anagnostopoulos A, Aleman A, Yang Y, Donato M, Weber D, Champlin R, Smith T, Alexanian R, Giralt S. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplant 33(6):623-8, 3/2004. PMID: 14730336.
37. Donato ML, Aleman A, Champlin RE, Weber D, Alexanian R, Ippoliti CM, de Lima M, Anagnostopoulos A, Giralt S. High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma 45(4):755-9, 4/2004. PMID: 15160952.
38. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103(8):3175-84, 4/2004. PMID: 15070700.
39. Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, Alexanian R, Giralt S. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 100(12):2607-12, 6/2004. PMID: 15197803.
40. Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 34(3):229-34, 8/2004. PMID: 15170166.
41. Dimopoulos MA, Alexanian R, Gika D, Anagnostopoulos A, Zervas C, Zomas A, Kyrtsonis MC, Anagnostopoulos N, Pangalis GA, Weber DM. Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma 45(10):2057-61, 10/2004. PMID: 15370250.
42. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal BB, Estrov Z. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 93(1):70-80, 7/2005. PMID: 15970928.
43. Wang M, Weber DM, Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 79(3):194-7, 7/2005. PMID: 15981221.
44. Merzianu M, Jiang L, Lin P, Wang X, Weber DM, Vadhan-Raj S, Nguyen MH, Medeiros LI, Bueso-Ramos CE. Nuclear BCL-10 Expression is Common in Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia and does not correlate with p65 NF-kappaB Activation. Mod Pathol 19((7)):891-898, 7/2006.
45. Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A, Champlin RE, Giralt SA. Risk Factors for Relapse After Complete Remission with High-dose Therapy for Multiple Myeloma. Leuk Lymphoma 47(7):1360-1364, 7/2006.
46. Donato M, Feasel A, Weber D, Prieto V, Giralt S, Champlin R. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 107:463-466, 2006.
47. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. Biol Blood Marrow Transplant 13(9):1066-72, 09/2007, 9/2007. PMID: 17697969.
48. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators. Lenalidomide Plus Dexamethasone for Relapsed Multiple Myeloma in North America. N Engl Med 357((21)):2133-2142, 11/2007.
49. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Debriaci P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation in safe and feasible in elderly patients with mulitple myeloma. Bone Marrow Transplantation 39:279-283, 2007.
50. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM,Weber D, Yahalom J, Yunus F. Multiple Myeloma. Clinical practice guidelines in oncology. National Comprehensive Cancer Network 5(2):118-47, 2007.
51. Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R 3rd, Breitz H, Alexanian R, Giralt S. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166) Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant 13(5):543-9, 2007.
52. Anderson K, Kyle R, Rajkumar SV, Stewart K, Weber D, Richardson P. ASH/FDA Workshop on Clinical Endpoints in Multiple Myeloma. Leukemia 22((2)):231-239, 2/2008.
53. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson P, San Miguel J, Barlogie B, Harousseau J, Zonder J, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig J, Vesole D, Blade J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, Lonial S, Morgan G, Orlowski R, Shimzu K, Anderson K, Boccardoro M, Durie BG, Hussein MA. Prevention of thalidomide and lenalidomide associated thrombosis in myeloma. Leukemia 22((2)):414-423, 2/2008.
54. Campagnaro E, Saliba R, Giralt S, Roden L, Mendoza F, Aleman A, Cleeland C, Weber D, Brown J, Anderson KO. Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer 1(112(7)):1617-1624, 4/2008.
55. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112(12):4445-4451, 9/2008. PMID: 18799726.
56. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14(12):1401-7, 12/2008. PMID: 19041063.
57. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):718-723, 6/2009. PMID: 19450756.
58. Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, Facon T, Olesnyckyj M, Yu Z, Zeldis JB, Knight RD, Dimopoulos MA. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 82(6):426-32, 6/2009. PMCID: PMC2704925.
59. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-6, 7/2009. PMID: 19539212.
60. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw 7(9):908-42, 10/2009. PMID: 19878637.
61. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23(11):2147-52, 11/2009. e-Pub 7/2009. PMID: 19626046.
62. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, Fink L. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 28(1):132-5, 1/2010. PMID: 19901114.
63. Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 150(1):28-38, 7/2010. PMID: 20507313.
64. Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM, Masliak Z, Reece D, Olesnyckyj M, Yu Z, Weber DM. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 116(16):3807-14, 8/2010. PMID: 20564094.
65. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-52, 10/2010. PMID: 20805315.
66. Harousseau JL, Dimopoulos MA, Wang M, Corso A, Chen C, Attal M, Spencer A, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. The quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 10:1738-44, 10/2010. PMID: 20460639.
67. San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 11(1):38-43, 2/2011. PMID: 21273172.
68. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152(5):579-92, 3/2011. e-Pub 1/2011. PMID: 21241278.
69. Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS. Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy. Cancer 117(19):4468-74, 10/1/2011. e-Pub 3/22/2011. PMID: 21437886.
70. Ishak KJ, Caro JJ, Drayson MT, Dimopoulos M, Weber D, Augustson B, Child JA, Knight R, Iqbal G, Dunn J, Shearer A, Morgan G. Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. Value Health 14(5):672-8, Jul-Aug, 7/2011. PMID: 21839405.
71. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, on behalf of the International Myeloma Working Group, International Myeloma Working Group, Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben-Yehuda D, Bensinger B, Leif Bergsagel P, Bird J, Bladé J, Boccadoro M, Cavo M, Chanan-Khan A, Ming Chen W, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, Leleu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nari H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Vincent Rajkumar S, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, Miguel JS, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Broek IV, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia. e-Pub 7/2011. PMID: 21799510.
72. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 1/2012. e-Pub 8/24/2011. PMID: 21780997.
73. Sweeney SA, Kumar VA, Tayar J, Weber DM, Safdar A, Alonso C, Hymes S. Case 181. Radiology 262(1):361-3, 1/2012. PMID: 22190660.
74. Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, Morgan GJ. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 119(12):2764-2767, 3/22/2012. e-Pub 2/9/2012. PMID: 22323483.
75. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 3/2012. e-Pub 1/9/2012. PMID: 22231283.
76. Sweeney SA, Kumar VA, Tayar J, Weber DM, Safdar A, Alonso C, Hymes S. Case 181: synovitis acne pustulosis hyperostosis osteitis (SAPHO) syndrome. Radiology 263(2):613-7, 5/2012. PMID: 22517965.
77. Chanan-Khan AA, Lonial S, Weber D, Borrello I, Foà R, Hellmann A, Dimopoulos M, Swern AS, Knight R. Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients 65 years old with relapsed or refractory multiple myeloma. Int J Hematol 96(2):254-62, 8/2012. e-Pub 7/2012. PMID: 22752567.
78. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma. Blood 120(16):3260-70, 10/18/2012. e-Pub 8/29/2012. PMCID: PMC3476538.
79. Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L, Hardwick JS, Jagannath S. Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk 12(5):319-24, 10/2012. PMID: 23040438.
80. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA, NCCN (National Comprehensive Cancer Network). Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013. J Natl Compr Canc Netw 10(10):1211-1219, 10/1/2012. PMID: 23054875.
81. Alexanian R, Delasalle K, Wang M, Thomas S, Weber D. Curability of multiple myeloma. Bone Marrow Res 2012:916479, 2012. e-Pub 5/23/2012. PMCID: PMC3366198.
82. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implications. Exp Hematol 41(8):719-30, 8/2013. e-Pub 5/2013. PMCID: PMC3769691.
83. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R. Multiple myeloma, version 1.2013. J Natl Compr Canc Netw 11(1):11-7, 1/2013. PMID: 23307977.
84. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a Role for CD44 and Cell Adhesion in Mediating Resistance to Lenalidomide in Multiple Myeloma: Therapeutic Implications. Leukemia 28(2):373-83, 2/2014. e-Pub 6/13/2013. PMCID: PMC3874423.
85. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122(14):2331-2337, 10/2013. e-Pub 8/2013. PMID: 23950178.
86. Cardoso RC, Gerngross PJ, Hofstede TM, Weber DM, Chambers MS. The multiple oral presentations of multiple myeloma. Support Care Cancer 22(1):259-267, 1/2014. e-Pub 9/20/2013. PMID: 24048519.
87. Alexanian R, Wang M, Delasalle K, Wang S, Qazilbash M, Handy B, Weber D. Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplant. e-Pub 12/2013. PMID: 24317125.
88. Wuu A, Bangert SD, Weber DM, Hymes SR. Primary cutaneous plasmacytoma. Cutis 93(6):E19-21, 6/2014. PMID: 24999652.
89. Liu Z, Xu J, He J, Zheng Y, Li H, Lu Y, Qian J, Lin P, Weber DM, Yang J, Yi Q. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood 124(13):2061-71, 9/25/2014. e-Pub 7/21/2014. PMCID: PMC4186536.
90. Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol 7(1):41, 2014. e-Pub 5/2014. PMCID: PMC4038108.

Invited Articles

1. Thomas SK, Richards TA, Weber DM. Novel agents for relapsed and/or refractory multiple myeloma. Cancer J 15(6):485-93, Nov-Dec, 11/2009. PMID: 20010168.
2. Thomas SK, Richards TA, Weber DM. Lenalidomide in Multiple Myeloma. Best Pract Res Clin Haematol 20((4)):717-735, 12/2007.
3. Weber DM. Solitary Bone and Extramedullary Plasmacytoma. Hematology (ASH Education Book):373-376, 2005.
4. Weber D. Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control 10(5):375-83, 9/2003. PMID: 14581892.
5. Weber D. Thalidomide and its Derivatives: New Promise for Multiple Myeloma. Cancer Control 10(5):375-383, 9/2003.
6. Dimopoulos M, Weber D, Hester J, Delasalle K, Champlin R, Alexanian R. Intensive sequential therapy for VAD-resistant multiple myeloma. Leukemia & Lymphoma 13:479-484, 1994.

Editorials

1. Alexanian R, Weber D. Whither Interferon for myeloma and other hematologic malignancies? Annals of Internal Medicine (Editorial) 124:264-265, 1996.

Abstracts

1. Shah, JJ, Hegde, A, Zhou, X, Thomas, S, Wang, M, Weber, DM, Alexanian, R, Orlowski, RZ, Vadhan-Raj, S. Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE. Blood (ASH Annual Meeting Abstracts) 120:2244, 2012.
2. Kuiatse, I, Thomas, SK, Weber, DM, Stein, AM, Wang, M, Shah, JJ, Treon, SP, Ansell, SM, Orlowski, RZ. Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia. Blood (ASH Annual Meeting Abstracts) 120:3723, 2012.
3. Thomas S, Hosing C, Delasalle K, Gavino M, Popat U, Qazilbash M, Giralt S, Weber D,. Success Rates of Autologous Stem Cell Collection in Patients with. 5th International Workshop on Waldenström’s, 10/2008.
4. Weber DM, Jagganath S, Mazumder A, Sobecks R, Schiller GJ, Gavino M, Meehan K, McFadden C, Chen C, Ricker JL, Rizvi S, Oerth C, Brownell P, Sanz-Rodriguez C, Hussein MA. Phase I trial of oral vorinostat in combination with bortezomib in advanced multiple myeloma. Haematologica 93((s1)) (#640), 6/2008.
5. Weber DM, Spencer A, Wang M, Cheri C, Attal M, Niesvizky R, Prince M, Yu Z, Knight R, Dimopoulos MA. The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma patients with impaired renal function. Journal of Clinical Oncology 26(15S):464s (#8542), 5/2008.
6. Giralt S, Thandi R, Qazilbash M, Mendoza F, Han E, Hosing C, Wang M, Thomas S, Alexanian R, Champlin R, Weber D. Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD). Blood 110(948), 12/2007.
7. Qazilbash MH, Saliba R, Parikh GC, Hosing C, Mendoza F, Weber DM, Wang M, Thomas SK, Flosser TS, Kebriaei P, Popat U, Alousi A, de Lima M, Champlin R, and Giralt S. A non-myeloablative regimen of fludarabine and melphalan is safe and well tolerated for allogeneic transplantation in multiple myeloma. Blood 110:3032, 11/2007.
8. Qazilbash M, Saliba R, Parikh G, Hosing C, Mendoza F, Qureshi S, Weber DM, Wang M, Flosser T, Couriel D, Kebriaei P, Popat U, Alousi A, de Lima M, Champlin R, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan Is Safe and Effective for Autotransplantation for Multiple Myeloma. Blood 110(942), 11/2007.
9. Parikh G, Saliba R, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi A, Champlin RE, Giralt S, and Qazilbash MH. Autotransplantation in patients with multiple myleoma and concurrent renal failure is safe and feasible and associated with recovery of renal function in > 30% of patients. Blood 110:5126, 11/2007.
10. Wright J, Weber D, Thomas SK, Wang M, Alexanian R, Hawkins VE, and Vadhan-Raj S. Characteristics of patients experiencing thromboembolic events during treatmetn for mutiple myeloma: aspirin may not be adequate thrombophylaxis in patients with multiple risk factors. Blood 110:1882, 11/2007.
11. Vadhan-Raj S, Wever DM, Wang M, Giralt S, Thomas SK, Alexanian R, Zhou X, Patel P, Bueso-Ramos CE, Newman R, Aggarwal BB. Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: results of a Phase I/II study. Blood 110:1177, 11/2007.
12. San Miguel JF, Dimopoulos M, Weber D, Olesnyckyj M, Yu Z, Zeldis J, Knight R, and Rajkumar V. Dexamethasone dose adjustments relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 Sub-Analysis). Blood 110:1172, 11/2007.
13. Chanan-Khan AA, Dimopoulos M, Weber D, Olesnysckyj M, Yu Z, Zeldis J, Knight R, and San Miguel J. ECOG Performance status affects efficacy, but not safety, of lenalidomide/dexamethasone in relapsed/refractory multiple myeloma (MM009/010 Sub-Analysis). Blood 110:2721, 11/2007.
14. Silva L, Weber D, Wang M, Han E, Mendoza F, de Lima M, Qazilbash M, Champlin R, Giralt S. Myeloma with AL amyloidosis: 10 years experience with stem cell transplant. Blood 110:5112, 11/2007.
15. Weber DM, Jagannath S, Mazumder A, Sobecks R, Schiller GJ, Gavino M, Sumbler C, McFadden C, Chen C, Ricker JL, Rizvi S, Oerth C, Brownell P, and Hussein MA. Phase I trial of oral vorinostat (suberolynalide hydoxamic acid, SAHA) in combination with bortezomib in patients wiht advanced multiple myeloma. Blood 110(1172), 11/2007.
16. Weber D, Knight R, Chen C, Spencer A, Yu Z, Zeldis J, Olesnyckvj M, and Dimopoulos M. Prolonged overall survival with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma. Blood 110:412, 11/2007.
17. Harousseau JL, Weber D, Dimopoulos M, Olesnyckyj M, Yu Z, Zeldis J, Knight R, and Siegel D. Relapsed/Refractory multiple myeloma patients treated with lenalidomide/dexamethasone who achieve a complete or near complete response have longer overall survival and time to progression compared with patients achieving a partial reponse. Blood 110:3598, 11/2007.
18. Thomas S, Delasalle K, Gavino M, Wang M, Alexanian R, wEBER dm. 2-CDA-cycophosphamide + rituximab for symptomatic Waldenstrom’s macroglobulinemia. Haematologica. Haematologica 92 (s2):228, 5/2007.
19. Wang M, Delasalle K, Thomas S, s, Qazilbash M, Giralt S, Weber DM, Alexanian R. Early transplant is useful for older patients with multiple myeloma. Haematologica 92 (s2):189, 5/2007.
20. Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SR, Facon T, Alexanian R, Yu Z, Zeldis J, Lesnyckij M, Weber DM. Effect of len/dex in mm despite thal resistance. Haematologica 92((s2)):172, 5/2007.
21. Lonial S, Knight R, Dimopoulos M, Chanan-Khan A, San Miguel J, Facon T, Yu Z, Zeldis J, Olesnyckyi M, Weber D. Effect of len/dex in mm in different age groups. Haematoogica((s2)):172, 5/2007.
22. Richards T, Horowitz S, Temple S. Nguyen C, Thomas S. Wang M, Giralt S, Weber DM. Evaluation of multiple myeloma response by free light chain assay. Haematologica 92(6):205, 5/2007.
23. Delasalle K, Wang M, Thomas S, Weber D, Alexanian R. High response rate with BCD combination for relapsing multiple myeloma. Haematologica 92((s2):189), 5/2007.
24. Weber DM. High response rate with BCD combination for relapsing multiple myeloma. Haematologica 91 (s2):158, 2007.
25. Weber DM. Lenalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma. Haematologica 92 (s2):22-23, 2007.
26. Thomas S, Delasalle K, Wang M, Alexanian R, Weber DM. Rituximab alone or in combination in the frontline treatment of Waldenstrom's macroglobulinemia. Haematologica 92 (s2):87-88, 2007.
27. Alexanian R, Weber D. Solitary bone and extramedullary plasmacytoma. Haematologica 92(s2):57-58, 2007.
28. Qazilbash M, Saliba R, Hosing C, Mendoza F, Qureshi S, Weber D, Weber D, Wang M, Flosser T, Couriel D, De Lima M, Kebriaei P, Popat U, Alousi A, Champlin R, Giralt S. Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma. Blood:page 450b, 12/2006.
29. Ahmed B, Saliba R, Ashraf N, Mendoza F, Hosing C, Flosser T, Weber D, Wang M, Couriel D, Popat U, Kebriaei P, Alousi A, Champlin R, Giralt S, Qazilbash M. Deletion of the Short Arm of Chromosome 1 (del 1 p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. Blood:Page 881a, 12/2006.
30. Chanana-Khan, Yu Z, Weber D, Chen C, Niesvizky R, Spencer A, Attal M, Belch A, Prince M, Olesnyckyi M, Knight R, Zeldis J, Dimopoulos M. Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials. Blood:1015a, 12/2006.
31. Stadmauer E, Weber D, Dimopoulos M, Belch A, Attal M, Prince M, Olesnyckyj M, Yu Z, Zeldis J, Knight R. Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma. Blood:page 1012a, 12/2006.
32. Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Alexanian R, Yu Z, Zeldis J, Olesnyckyj M, Weber D. Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma. Blood:1014a, 12/2006.
33. Weber D, Wang M, Chen C, Belch A, Stadmauer E, Niesvisky R, Yu, Olesnyckyi M, Zeldis J, Knight R, Dimopoulos M. Lenalidomide plus high dose dexmethasone provides improved overall survival compared to high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. Blood 18S:24 (#3547), 12/2006.
34. Wang M, Knight R, Dimopoulos M, SiegelD, Rajkumar SV, Facon T, Yu Z, Zeldis j, Olesnycky J, Weber DM. Lenalidomide in combination with dexamethasone is more effective than dexamethasone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma (MM). Journal of Clinical Oncology 24, No. 18S (June 20 Supplement):7522, 5/2006.
35. Qazibash M, Saliba R, Davis M, Mendoza F, Hosing C, Couriel D, De Lima M, Debriaei S, Weber D, Wang M, Alousi A, Matthes S, Jones R, Champlin R, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood:881a, 2006.
36. Chanan-Khan A, Weber D, Dimopoulos M, Chen C, Niesvizky R, Wang M, Belch A, Attal M, Spencer A, Prince M, Olesnycky M, Zeldis J, Yu Z, Knight R. Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM). Blood:1012a, 2006.
37. Thomas S, Giralt S, Wang M, Delasalle K, Gavino M, Rankin K, Alexanian R, Weber D. Survival Outcomes of Patients Receiving Thalidomide-Dexamethasone for Previously Untreated Multiple Myeloma. Blood:page 1019a, 2006.
38. Wang M, Talpaz M, Jagannath S, Chanan-Khan A, Alexanian R, Weber D, Gavino M, Estrov Z, Harris P, Picker D, Schlossman R, Tassone P, Anderson K, Munshi N. A phase I, multicenter dose escalation study of atiprimod in patients with refractory or relapsed multiple myeloma. Blood Abstract 111:36a, 2005.
39. Wang, M, Alexanian R, Delasalle KB, Weber DM. Confirmation of the Prognostic Value of the International Staging System for Multiple Myeloma proposed by the International Myeloma Working Group and Southwest Oncology Group Staging System using B2microglobulin alone. Haematologica 90(Abstract pO. 308):97, 2005.
40. Christoforidou A, Williams P, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Breitz H, Alexanian R, Champlin R, Giralt S. Impact of holmium-DOTMP on transplant outcomes for multiple myeloma. Blood (#426), 2005.
41. Weber D. Lenalidomide (CC-5013, Revlimid) and other IMiDs. . Haematologica 90(51, Abstract PL5.02):24-25, 2005.
42. Weber, DM, Chen C, Niesvizkyr. Multi-Center, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study of Lenalidomide plus Dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma. Haematologica 90((51) Abstract PO. 738):155, 2005.
43. Weber, D, Wang M, Delasalle K, Gavino M, Alexanian R. 2-chlorodeoxyadenosine and cyclophosphamide alone, or in combination with rituximab, for previously untreated Waldenstrom’s macroglobulinemia. American Society of Hematology (Blood)(Abstract 1476):413a, 2004.
44. Weber, DM, LM Wang, KB Delasalle, T Smith, RAlexanian. Prognostic features of asymptomatic multiple myeloma. International Multiple Myeloma Conference:71-72, 2004.
45. Moulopoulos, L, Gika D, Delasalle K, Weber D, Anagnostopoulos M, Alexanian R. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. American Society of Hematology (Blood)(Abstract 1485):415a, 2004.
46. Alexanian, R, DWeber, MWang, KDelasalle. Thalidomide-Dexamethasone as primary treatment for multiple myeloma, and role of added Bortezomib. International Multiple Myeloma Conference:164-5, 2004.
47. Alexanian, R, Wang L, Weber D, Delasalle K. Velcade, thalidomide, dexamethasone as primary therapy for newly-diagnosed multiple myeloma. American Society of Hematology (Blood)(Abstract 210):64a, 2004.
48. Wang, M, Alexanian R, Delasalle K, Weber D. Abnormal MRI of spine is the dominant risk factor for early progression of asymptomatic multiple myeloma. American Society of Hematology (Blood(Abstract 2546):687a, 2003.
49. Weber, D, Wang M, Delasalle K, Alexanian R. Confirmation of prognostic value of model using B2M alone. American Society of Hematology (Blood)(Abstract 3491):937a, 2003.
50. Alexanian, R, Weber D, Delasalle K, Wang M, Giralt S, Champlin R. Frequency and impact of complete remission with intensive therapy for multiple myeloma. The Hematology Journal(V4 (S1)):S245(352), 2003.
51. Alexanian, R, Weber D, Delasalle K, Wang M, Champlin R, Giralt S. Progressively reduced sensitivity of multiple myeloma to serial intensive therapies. American Society of Hematology (Blood).(Abstract 3654):982a, 2003.
52. Alexanian, R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide alone or with dexamethasone for resistant or relapsing multiple myeloma. The Hematology Journal 4:S2, 2003.
53. Wang, M, Weber D, Delasalle K, Rankin K, Gavino M, Alexanian R. Thalidomide-dexamethasone as primary therapy for multiple myeloma of high tumor mass. The Hematology Journal 4(S1):S245 (352), 2003.
54. Weber, D, Treon SP, Emmanoulides C. Uniform response criteria in waldenstrom’s macroglobulinemia. Consensus panel IV recommendations from the second international workshop on waldenstrom’s macroglobulinemia, The Hematology Journal 4:S1, 2003.
55. Alexanian, R, Weber D, Delasalle K, Cabanillas F, Dimopoulos M. Cabanillas F, Dimopoulos M. Asymptomatic Waldenstrom’s disease. American Society of Hematology (Blood)(Abstract 2377):604a, 2002.
56. Weber, D, Albitar M, Delasalle K, Dey A, Rankin K, Gavino M, Walker P, Alexanian R. Correlation of peripheral blood plasma levels of angiogenesis factors with treatment of thalidomide or thalidomide dexamethasone in previously untreated patients with multiple myeloma. American Society of Hematology, Blood.(Abstract 3193):808a, 2002.
57. Weber, D, Ginsberg C, Walker P, Aholendt M, Rankin K, Gavino M, Delasalle K, Alexanian R. Correlation of Thrombotic/Embolic Events with Features of Hypercoagulability in Previously Untreated Patients before and after Treatment with Thalidomide or Thalidomide-dexamethasone. American Society of Hematology (Blood:209a, 2002.
58. Alexanian, R, Weber D, Delasalle K, Giralt S, Champlin R. Value of Intensive Therapy Supported by Autologous Stem Cells for Primary Resistant Multiple Myeloma. American Society of Hematology (Blood)(Abstract 672):180a, 2002.
59. Wang, M, Weber D, Fourney D, Burton A, Schomer D, Ahrar K, Gokaslan Z, Alexanian R. Value of vertobroplasty and kyphoplasty for painful verletual compressions in multiple myeloma. American Society of Hematology (Blood)(Abstract 1565):403a, 2002.
60. Weber, D, Dimopoulos M, Rankin K, Gavino M, Delasalle K, Cabanillas F, Alexanian R. A decade of experience: Primary treatment of Waldenstrom’s macroglobulinemia with 2-chlorodeoxyadenosine alone or in combination. American Society of Hematology (Blood):635a, 2001.
61. Anagnostopoulos, A, Aleman A, Williams P, Weber D, Donato M, Alexanian R, Champlin R, Giralt S. Autologous stem cell transplantation after nonmyelosuppressive induction therapy with dexamethasone alone is safe and effective for newly diagnosed multiple myeloma patients who receive high dose chemotherapy. American Society of Hematology (Blood)(Abst. 2858):683a, 2001.
62. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. American Society of Hematology (Blood) Abst 686:163a (#635a), 2001.
63. Alexanian, R, Weber D, Delasalle K, Giralt S, Champlin R. Frequency and impact of complete remission in patients with multiple myeloma of low tumor mass who received intensive therapy supported by autologous stem cell transplantation. American Journal of Hematology (Blood)(Abst. 3530):850a, 2001.
64. Wilder, R, Ha C, Cox J, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than 1 year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. American Journal of Hematology (Blood)(Abst 3524):849a, 2001.
65. Rankin, K, Delasalle K, Gavino M, Alexanian R, Weber D. Progressive decline of myeloma patients referred with advanced disease. VIII International Myeloma Workshop(Abst P106):169, 2001.
66. Giralt, S, Champlin R, Alexanian R. Results of a Phase I/II trial with 166 Ho-DOTMP plus high dose chemotherapy in patients with multiple myeloma. VIII International Myeloma Workshop(Abst S 24):40-41, 2001.
67. Delasalle, K, Gavino M, Rankin K, Weber D, Alexanian R. Short survival of older myeloma patients has not improved for 25 years. VIII International Myeloma Workshop(Abst P105):169, 2001.
68. Weber, D, Rankin K, Delasalle I, Gavino M, Alexanian R. Thalidomide alone and in combination for previously untreated myeloma. VIII International Myeloma Workshop(Abst S 66):109-110, 2001.
69. Weber, D, Rankin K, Gavino M, Delasalle K, Aguayo A, Albitar M, Alexanian R. Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma. American Society of Hematology (Blood)(Abst 724):168a, 2000.
70. Donato, MChu D, Alexanian R, Weber D, Korbling M, Giralt S, Champlin R. Filgrastim alone versus chemotherapy plus filgrastim for peripheral blood stem cell mobilization in multiple myeloma. American Society of Hematology (Blood)(Abst 783):182a, 2000.
71. Giralt, S, Bensinger W, Wendt R, Williams P, Alexanian R, Weber D, Bryan J, Thoelke K, Ha C, McCullough S, Champlin R. Hemorrhagic cystitis after targeted radiotherapy with 166 Holmium-DOTMP for multiple myeloma is preventable with bladder irrigation. American Society of Hematology (Blood)(Abst 1686):391a, 2000.
72. Donato, M, Champlin R, Weber D, Alexanian R, Ippoliti C, Aleman A, Cooke S, Martin T, De Lima M, Giralt S. High-dose topotecan, melphalan and cyclophosphamide in multiple myeloma. American Society of Hematology (Blood)(Abst 3446):798a, 2000.
73. Weber, D, Dimopoulos M, Gavino M, Delasalle K, Rankin K, Alexanian R. Nucleoside analogues: new combinations for treatment of Waldenstrom’s macroglobulinemia. 1st International Symposium on Waldenstrom’s Macroglobulinemia,:10, 2000.
74. Weber, DM, Wang LM, Delasalle KB, Smith T, Alexanian R. Risk factors for early progression asymptomatic multiple myeloma. The Hematology Journal 4(S1):S31, 2000.
75. Weber, D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide with dexamethasone for resistant multiple myeloma. American Society of Hematology (Blood)(Abst 719):167a, 2000.

Book Chapters

1. Thomas S, Richards T, Weber D. Lenalidoide: relapsed disease. In lonial S (ed). In: Contemporary Hematology: Myeloma Therapy: Pursuing the Plasma Cell. Humana Press: Totowa, NJ, 265-278, 2008.
2. Thomas S, Richards T, Weber D. Novel Agents for Previously Untreated Multiple Myeloma. In: Multiple Myeloma: Translational and Emerging Therapies. Ghobrial I and Anderson K (Ed). Informa healthcare. Informa Healthcare: New York, 141-167, 2007.
3. Seymour G, Wang M, Lin P, Weber D. Multiple Myeloma and Other Plasma Cell Dyscrasias in Kantarjian HM. In: MD Anderson Manual of Medical Oncology: Houston, 175-193, 2006.
4. Weber Donna. Thalidomide treatment. In: Multiple Myeloma, 79-83, 2004.
5. Weber DM. Multiple myeloma and plasma cell dyscrasias. In: Cancer Management: A Multidisciplinary Approach. PRR Publications(in press)., 2000.
6. Weber D. Multiple Myeloma Guidelines. In: Color Matrix Cancer staging and treatment handbook, 3rd ed.,, 45, 130, 2000.
7. Weber DM. Multiple Myeloma and Other Plasma Cell Dyscrasias. In: MKSAP in the subspecialty of hematology, 1999.
8. Waxman, ES, Weber DM. Multiple myeloma and other plasma cell dyscrasias. In: Primary Care Oncology, 339-352, 1999.
9. Weber DM:. Multiple myeloma and plasma cell dyscrasias . In: Cancer Management: A multidisciplinary approach, 1999.
10. Buzaid, AC, Weber DM. Abnormal serum protein electrophoresis. In: Decision making in medicine an algorithmic approah , (ed.2), 236-239, 1998.
11. Papadimitrakopoulou, V, Weber DM. Multiple myeloma and other plasma cell dyscrasias. In: Medical Oncology: A Comprehensive Review, 127-135, 1996.
12. Alexanian, R, Dimopoulos M, Weber D, Delasalle K, Hester J, Champlin R. Intensive sequential therapy for VAD-resistant multiple myeloma. Multiple Myeloma and Related Disorders. In: Challenges of Modern Medicine. 4. Ares-Serona Symposia Publications, 175-182, 1994.
13. Weber, DM, Alexanian R. Multiple myeloma and other plasma cell dyscrasias. In: Medical Oncology: A Comprehensive Review, 49-58, 1993.

Books (edited and written)

1. Richards T, Weber D. Advances in treatment for relapses and refractory multiple myeloma. In: Med Oncol. 27 Suppl 1, 2010. ISBN: 20213220.

Letters to the Editor

1. Weber, DM, Daliani D, Alexanian R. Clinical Problem Solving: costly errors. N Engl J. Med 333:1080, 1995.
2. Weber, DM, Pugh WC, Steinbach G. Cure of gastric lymphoma with antibiotics. Gastroenterology 109:334-335, 1995.
3. Weber, DM, Dimopoulos MA, Alexanian R. Increased neurotoxicity with VAD-cyclosporin in mutliple myeloma. Lancet 341:558-9, 1993.
4. Dimopoulos, MA, Weber DM, Estey EE, Alexanian R. Primary treatment with 2-Chlorodeoxyadenosine of low grade lymphomas that produce IgG or IgA immunoglobulin. Am J Hematol:326-27, 1993.

Grant & Contract Support

Title: Targeting NF-kappa B by Curcumin for Chemoresistance in Multiple Myeloma
Funding Source: Center for Targeted Therapy
Role: Co-Principal Investigator
Principal Investigator: Aggarwhal, MD
Duration: 2008
 
Title: Treatment of Macroglobulinemic Lymphoma with 2CdA and Cyclophosphamide
Funding Source: MDACC
Role: Principal Investigator
Duration: 5/15/1996 - 4/10/1998

Last updated: 11/4/2014